



ESGICH

ESCMID STUDY GROUP FOR INFECTIONS IN COMPROMISED HOSTS

European Society of Clinical Microbiology and Infectious Diseases

Objectives

The ESCMID Study Group for Infections in Compromised Hosts was created in December 2010 with the aim of promoting research and education in prevention, diagnosis and therapy of infections in immunocompromised hosts and in solid organ transplant (SOT) recipients

Completed Activities

1. Educational

ESGICH@ECCMID 2018 Madrid, Spain:

- **ECCMID 2018 Madrid Educational Workshop (2 hours):** Tropical diseases and travel medicine in solid organ transplant (SOT) recipients; co-arranged with: ESGITM - ESCMID SG for Infections in Travellers and Migrants, ESGICH - ESCMID SG for Infections in Compromised Hosts
- **ECCMID 2018 Madrid Meet-the-Expert:** How to optimize the management of CMV infection in transplant patients; co-arranged with: ESGICH - ESCMID SG for Infections in Compromised Hosts
- **ECCMID 2018 Madrid Meet-the-Expert:** Treating the treatment: infections in critically ill patients requiring ECMO; co-arranged with: ESGICH - ESCMID SG for Infections in Compromised Hosts, EPASG - ESCMID PK/PD of Anti-Infectives SG
- **ECCMID 2018 Madrid Symposium (1 hour):** Viruses in transplantation - not always enemies; co-arranged with: ESGICH - ESCMID SG for Infections in Compromised Hosts
- **ECCMID 2018 Madrid Symposium (2 hour):** Infections and biologicals: a real concern?; co-arranged with: ESGICH - ESCMID SG for Infections in Compromised Hosts
- **ECCMID 2018 Madrid Symposium (2 hour):** Stubborn' infections in transplant patients - from recurrence to resistance; co-arranged with: ESGICH - ESCMID SG for Infections in Compromised Hosts

ESGICH meetings & conferences outside the ECCMID

- Antimicrobial Therapy in Immunocompromised and Critically Ill Patients: Management and Perspectives. 4th-5th October 2018. Lugano, Switzerland.

2. Publications, guidelines and consensus documents, research activities

1. **Aguado JM, Manuel O.** Editorial for ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective. *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S1. doi: 10.1016/j.cmi.2018.04.029.
2. **Fernández-Ruiz M, Meije Y, Manuel O, Akan H, Carratalà J, Aguado JM, Delaloye J.** ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction). *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S2-S9. doi: 10.1016/j.cmi.2018.01.029. Epub 2018 Feb 7. Review.
3. **Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J.** ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor- α agents). *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S10-S20. doi: 10.1016/j.cmi.2017.12.025. Epub 2018 Feb 6. Review.
4. **Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, Fernández-Ruiz M, Grossi P, Aguado JM.** ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S53-S70. doi: 10.1016/j.cmi.2018.02.009. Epub 2018 Feb 16. Review.
5. **Mikulska M, Lanini S, Gudiol C, Drgona L, Ippolito G, Fernández-Ruiz M, Salzberger B.** ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S71-S82. doi: 10.1016/j.cmi.2018.02.003. Epub 2018 Feb 12. Review.
6. **Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M.** ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S21-S40. doi: 10.1016/j.cmi.2018.02.002. Epub 2018 Feb 12. Review.
7. **Redelman-Sidi G, Michielin O, Cervera C, Ribí C, Aguado JM, Fernández-Ruiz M, Manuel O.** ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S95-S107. doi: 10.1016/j.cmi.2018.01.030. Epub 2018 Feb 7. Review.
8. **Aguilar-Company J, Fernández-Ruiz M, García-Campelo R, Garrido-Castro AC, Ruiz-Camps I.** ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S41-S52. doi: 10.1016/j.cmi.2017.12.027. Epub 2018 Feb 7. Review.
9. **Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M.** ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). *Clin Microbiol Infect.* 2018 Jun;24 Suppl 2:S83-S94. doi: 10.1016/j.cmi.2018.03.022. Epub 2018 Mar 20. Review.
10. **Robert-Gangneux F, Meroni V, Dupont D, Botterel F, Garcia JMA, Brenier-Pinchart MP, Accoceberry I, Akan H, Abbate I, Boggian K, Bruschi F, Carratalà J, David M, Drgona L, Djurković-Djaković O, Farinas MC, Genco F, Gkrania-Klotsas E, Groll AH, Guy E, Hirtzel C, Khanna N, Kurt Ö, Junie LM, Lazzarotto T, Len O, Mueller NJ, Munoz P, Pana ZD, Roilides E, Stajner T, van Delden C, Villena I, Pelloux H, Manuel O.** Toxoplasmosis in Transplant Recipients, Europe, 2010-2014. *Emerg Infect Dis.* 2018 Aug;24(8):1497-1504.
11. **Coussement J, Maggiore U, Manuel O, Scemla A, López-Medrano F, Nagler EV, Aguado JM, Abramowicz D;** European Renal Association-European Dialysis Transplant Association (ERA-EDTA) Developing Education Science and Care for Renal Transplantation in European States (DESCARTES) working group and the European Study Group for Infections in Compromised Hosts (ESGICH) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. *Nephrol Dial Transplant.* 2018 Apr 9. doi: 10.1093/ndt/gfy078.
12. **Ullmann AJ, Aguado JM, Arikani-Akdaglı S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranal J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.** Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECCM-ERS guideline. *Clin Microbiol Infect.* 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002.
13. **Clemente WT, Pierrotti LC, Abdala E, Morris MI, Azevedo LS, López-Vélez R, Cuenca-Estrella M, Torre-Cisneros J, Petersen E, Camargo LFA, Wright AJ, Beeching NJ, Vilela EG, Santoro-Lopes G, Len O, Stucchi RSB, Manuel O, Faria LC, Leblebicioglu H, Huprikar S, Molina I, Mourão PHO, Kotton CN, Aguado JM;** working group on Endemic Disease and Travel Medicine in Solid-Organ Transplantation. Recommendations for Management of Endemic Diseases and Travel Medicine in Solid-Organ Transplant Recipients and Donors: Latin America. *Transplantation.* 2018 Feb;102(2):193-208.

Planned Activities

1. ESGICH@ECCMID 2019 Amsterdam, Netherlands:

- **1-Hour Symposium:** Microbiota and transplantation. Co-organised with ESGHAMI - ESCMID Study Group for Host And Microbiota Interaction
- **2-Hour Symposium:** Host-directed therapies for infectious diseases
- **Meet-the-Expert Session:** How to manage immunocompromised patients with central nervous system infection? Co-organized with ESCMID Study Group for Infectious Diseases of the Brain – ESGIB
- **2-hour Educational Workshop:** Neutropenia: the ups and downs of antibiotic therapy

2. ESGICH meetings & conferences outside the ECCMID

- Postgraduate educational course: JOINT ESGICH / EORTC / ICHS SYMPOSIUM Infections in Oncohematological Patients. Genova, 20.-21.May 2019. Directors: Malgorzata Mikulska and Claudio Viscoli

3. Ongoing Research Projects

- International practice survey on scedosporiasis in lung transplant candidates/recipients: EFISG and ESGICH. PI: Dr Blandine Rammaert and Pr Olivier Lortholary, France. Abstract accepted at ECCMID 2018. Manuscript in preparation
- Impact of antibiotic resistance on outcomes of neutropenic cancer patients with *Pseudomonas aeruginosa* bacteremia (IRONIC study). PI: Carlota Gudiol, Barcelona, Spain (Poster accepted at ECCMID 2019)
- Impact of β -lactam + aminoglycoside combination regimen as empirical therapy for the treatment of bacteremia due to Gram-negative bacilli in neutropenic hematologic patients in an era of antimicrobial resistance (AMINOLACTAM Study). PI: Carlota Gudiol, Barcelona, Spain
- Ceftolozane/tazobactam for the treatment of bacteremia due to MDR *Pseudomonas aeruginosa* occurring in neutropenic cancer patients (ZENITH study). PI: Carlota Gudiol, Barcelona, Spain
- Impact of specific antimicrobials and MIC values on the outcome of bloodstream infections due to ESBL- or carbapenemase-producing *Enterobacteriaceae* in Solid Organ Transplantation: an observational multinational study (INCREMENT-SOT Project). PI: Julián Torre-Cisneros, Jesús Rodríguez-Baño, Jose María Aguado, Álvaro Pascual, Luis Martínez-Martínez.

ESGICH @ ECCMID 2019 Amsterdam, Netherlands

- **Saturday 13.4.2019 13:30 – 15:30, Room G104/105 . ESGICH Business Meeting**
All interested persons are cordially invited to join the meeting and plan future ESGICH activities

Contact

Chairperson: Dr Oriol MANUEL, Switzerland (Oriol.Manuel@chuv.ch)

Vice-Chair: Pr Dr Bernd SALZBERGER, Germany
(bernd.salzberger@klinik.uni-regensburg.de)

Secretary: Dr Lubos DRGONA, Slovakia (lubos.drgona@nou.sk)

Treasurer: Pr Dr Hamdi AKAN, Turkey (hamdiakan@gmail.com)

Past Chair: Pr Dr Claudio VISCOLI, Italy (claudio.viscoli@unige.it)

Past Chair: Pr Dr Jose Maria AGUADO, Spain (jaguadog@medynet.com)

Member: Pr Dr Paolo GROSSI, Italy (paolo.grossi@uninsubria.it)